Clinical Trials Sponsored by Guided Therapeutics

Total 6409 results

Heron Therapeutics

Completed

A Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal Herniorrhaphy

Postoperative Pain

United States
Heron Therapeutics

Completed

Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy

Postoperative Pain | Bunions

United States
Intrinsic Therapeutics

Active, not recruiting

Post-Marketing Clinical Follow-Up of a Spine Implant (PMCFU)

Lumbar Disc Herniation | Annular Tear of Lumbar Disc

Germany, Switzerland
Intrinsic Therapeutics

Active, not recruiting

A Prospective, Randomized, Multicenter Study to Demonstrate the Superiority of the Barricaid to Discectomy for Primary Lumbar Disc Herniation

Lumbar Disc Herniation

Germany, Austria, Netherlands, Belgium, France, Switzerland
Better Therapeutics

Completed

Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes

Type 2 Diabetes

United States
Fate Therapeutics

Terminated

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Melanoma | Lymphoma | Renal Cell Carcinoma | Cervical Cancer | Head and Neck Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumor | Small-cell Lung Cancer | HER2-positive Breast Cancer | Pancreas Cancer | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability and other conditions

United States
Lyra Therapeutics

Completed

LYR-220 for Adult Subjects With Chronic Rhinosinusitis (BEACON Study)

Chronic Sinusitis | Chronic Rhinosinusitis (Diagnosis)

United States, Australia
Fate Therapeutics

Terminated

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Solid Tumor, Adult

United States
Fate Therapeutics

Terminated

FT538 in Subjects With Advanced Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Myeloma | AML, Adult

United States
Amicus Therapeutics

Completed

A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease (PROPEL)

Pompe Disease (Late-onset)

United States, Australia, Korea, Republic of, Japan, Taiwan, Belgium, Slovenia, New Zealand, United Kingdom, France, Argentina, Canada, Spain, Bosnia and Herzegovina, Germany, Sweden, Hungary, Austria, Bulgaria, Denmark, Greece, I... and more
Confo Therapeutics

Completed

Safety and Tolerability of CFTX-1554 in Healthy Subjects

Healthy

Netherlands
Heron Therapeutics

Completed

Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen

Analgesia

United States
MitoImmune Therapeutics

Completed

Clinical Trial to Evaluate Pharmacokinetic Characteristics of MIT-001 After SC Administration in Healthy Subjects

Heathly Subjects

Korea, Republic of
Karuna Therapeutics

Active, not recruiting

An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

Schizophrenia

United States
United Therapeutics

Completed

EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States
Elevar Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

Adenoid Cystic Carcinoma

United States, Korea, Republic of
Sage Therapeutics

Completed

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)

Parkinson Disease | Cognitive Dysfunction

United States
Intrommune Therapeutics

Completed

OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut

Peanut Allergy

United States
Lyra Therapeutics

Completed

LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study)

Chronic Sinusitis | Chronic Rhinosinusitis (Diagnosis)

Poland, Australia, New Zealand, Austria, Czechia
Freeline Therapeutics

Terminated

Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B

Hemophilia B

United States, United Kingdom
Spark Therapeutics

Completed

Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants

Hematologic Diseases | Hemophilia A | Blood Coagulation Disorders, Inherited | Coagulation Protein Disorders | Hemorrhagic Disorders | Genetic Diseases, Inborn | Genetic Diseases, X-Linked | Blood Coagulation Disorder | Factor VIII Deficiency

United States, Australia, Thailand, Canada
Tempest Therapeutics

Completed

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Sarcoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Cancer | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Non-small Cell Lung Cancer | Urothelial Carcinoma | GastroEsophageal Cancer | Triple-Negative Breast Cancer | Metastatic Castration Resistant Prostate...

United States
PTC Therapeutics

Terminated

A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19) (FITE19)

COVID-19 | Pneumonia | Coronavirus

Spain, United States, Australia, France, Brazil, Mexico, South Africa, Belgium, Colombia, Poland, Portugal
Encoded Therapeutics

Terminated

Natural History Study of Infants and Children With Developmental and Epileptic Encephalopathies (ENVISION)

Dravet Syndrome

United States, Spain, Australia, United Kingdom
Freeline Therapeutics

Terminated

A Fabry Disease Gene Therapy Study (MARVEL1)

Lysosomal Storage Diseases | Fabry Disease

United States, Norway, Germany, Austria, United Kingdom, Italy, Canada
Monopar Therapeutics

Terminated

Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer. (VOICE)

Chemoradiotherapy-Induced Severe Oral Mucositis

United States, Spain, Germany, France, Puerto Rico
101 Therapeutics

Active, not recruiting

101-PGC-005 for the Treatment of COVID-19

COVID-19

India
Celldex Therapeutics

Completed

A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria

Cold Urticaria | Symptomatic Dermographism | Cholinergic Urticaria | Cold Contact Urticaria | Symptomatic Dermatographism

Germany
Harpoon Therapeutics

Completed

Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression

Advanced Cancers Associated With Mesothelin Expression

United States
Corcept Therapeutics

Completed

Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC

Metastatic Castration-Resistant Prostate Cancer

United States, United Kingdom
Amicus Therapeutics

Completed

A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.

Fabry Disease

Japan, Taiwan, Turkey, United States, Brazil
Frequency Therapeutics

Terminated

First in Human Safety Study of FX-345 in Adults With Sensorineural Hearing Loss

Hearing Loss, Sensorineural

United States
Frequency Therapeutics

Completed

FX-322 in Adults With Acquired Sensorineural Hearing Loss

Hearing Loss, Sensorineural | Noise Induced Hearing Loss | Sudden Hearing Loss

United States
Tessa Therapeutics

Active, not recruiting

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma (CERTAIN)

Anaplastic Large Cell Lymphoma | Diffuse Large B Cell Lymphoma | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

United States
Serina Therapeutics

Active, not recruiting

A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214

Parkinson's Disease

United States
Effector Therapeutics

Completed

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

Solid Tumors

United States
Corcept Therapeutics

Completed

Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

Non-alcoholic Steatohepatitis (NASH) | Antipsychotic Induced Weight Gain

United States
Mahana Therapeutics

Completed

MHNA-001 for Young Adults With IBS

Irritable Bowel Syndrome

United States
101 Therapeutics

Terminated

A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care

COVID-19

Israel
Corcept Therapeutics

Completed

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Neoplasms | Cushing Syndrome

United States
OX2 Therapeutics

Active, not recruiting

Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma

Glioblastoma

United States
ProQR Therapeutics

Terminated

Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)

Eye Diseases | Retinitis Pigmentosa | Eye Diseases, Hereditary | Vision Disorders | Retinal Disease | Eye Disorders Congenital | Usher Syndrome Type 2 | Deaf Blind

United States, United Kingdom
Stemirna Therapeutics

Active, not recruiting

mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs

Efficacy | Safety | Immunogenicity

Lao People's Democratic Republic
ProQR Therapeutics

Terminated

An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (HELIA)

Retinitis Pigmentosa | Usher Syndrome Type 2

United States, Canada, France
ProQR Therapeutics

Completed

Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

Leber's Congenital Amaurosis

United States, Belgium
101 Therapeutics

Active, not recruiting

Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects

Virus Diseases | COVID-19 | Infectious Disease | Glucocorticoids Toxicity

India
Rubius Therapeutics

Terminated

RTX-240 Monotherapy and in Combination With Pembrolizumab

Solid Tumor, AML Adult

United States
Highlight Therapeutics

Terminated

Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis

Gastric Cancer | Colorectal Cancer | Oesophageal Cancer

Spain, Belgium, Italy
Rubius Therapeutics

Terminated

RTX-224 Monotherapy in Patients With Solid Tumors

Non Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Cutaneous Melanoma | TNBC - Triple-Negative Breast Cancer

United States
Pendulum Therapeutics

Completed

Evaluating Use of Continuous Glucose Monitors in a Short-term 2x2-Crossover Study

Diabetes Mellitus | Diabetes Type 2

United States

Clinical Trials Sponsored by Guided Therapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations